Literature DB >> 11602742

Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line.

C T Yeh1, H Y Lai, T C Chen, C M Chu, Y F Liaw.   

Abstract

Although hepatitis C virus E2 protein can bind to human cells by interacting with a putative viral receptor, CD81, the interaction alone is not sufficient to establish permissiveness for hepatitis C virus infection. Using an Epstein-Barr virus-based extrachromosomal replication system, we have screened through a human liver cDNA library and successfully identified a cDNA capable of supporting hepatitis C virus replication in an otherwise nonpermissive cell line. This cDNA encodes a protein exhibiting homology to a group of proteins derived from various evolutionarily distant species, including Oryza sativa submergence-induced protein 2A. The mRNAs encoding this factor are heterogeneous at the 5' ends and are ubiquitously expressed in multiple tissues, albeit in a very small amount. The longest mRNA contains an in-frame and upstream initiation codon and codes for a larger protein. This 5'-extended form of mRNA was detected in hepatocellular carcinoma, but not in normal liver tissue. Immunofluorescence analysis demonstrated that the hepatic factor was distributed evenly in cells, but occasionally formed aggregations in the peri- or intranuclear areas. In summary, we have identified a hepatic factor capable of supporting hepatitis C virus replication in an otherwise nonpermissive cell line. This factor belongs to a previously uncharacterized protein family. The physiological function of this protein awaits further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602742      PMCID: PMC114682          DOI: 10.1128/JVI.75.22.11017-11024.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.

Authors:  C T Yeh; R N Chien; C M Chu; Y F Liaw
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

2.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Structure-function analysis of hepatitis C virus envelope-CD81 binding.

Authors:  R Petracca; F Falugi; G Galli; N Norais; D Rosa; S Campagnoli; V Burgio; E Di Stasio; B Giardina; M Houghton; S Abrignani; G Grandi
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone.

Authors:  J E Hambor; C A Hauer; H K Shu; R K Groger; D R Kaplan; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

5.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.

Authors:  A Meola; A Sbardellati; B Bruni Ercole; M Cerretani; M Pezzanera; A Ceccacci; A Vitelli; S Levy; A Nicosia; C Traboni; J McKeating; E Scarselli
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Enhancement of hepatitis C virus replication by Epstein-Barr virus-encoded nuclear antigen 1.

Authors:  Y Sugawara; M Makuuchi; N Kato; K Shimotohno; K Takada
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

8.  Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.

Authors:  T Allander; X Forns; S U Emerson; R H Purcell; J Bukh
Journal:  Virology       Date:  2000-11-25       Impact factor: 3.616

9.  Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1.

Authors:  S C Hung; M S Kang; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

10.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

View more
  12 in total

Review 1.  The Metal Drives the Chemistry: Dual Functions of Acireductone Dioxygenase.

Authors:  Aditi R Deshpande; Thomas C Pochapsky; Dagmar Ringe
Journal:  Chem Rev       Date:  2017-07-21       Impact factor: 60.622

2.  Dual chemistry catalyzed by human acireductone dioxygenase.

Authors:  Aditi R Deshpande; Thomas C Pochapsky; Gregory A Petsko; Dagmar Ringe
Journal:  Protein Eng Des Sel       Date:  2017-03-01       Impact factor: 1.650

3.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  A Model for the Solution Structure of Human Fe(II)-Bound Acireductone Dioxygenase and Interactions with the Regulatory Domain of Matrix Metalloproteinase I (MMP-I).

Authors:  Xinyue Liu; Abigail Garber; Julia Ryan; Aditi Deshpande; Dagmar Ringe; Thomas C Pochapsky
Journal:  Biochemistry       Date:  2020-11-02       Impact factor: 3.162

5.  Metal-Dependent Function of a Mammalian Acireductone Dioxygenase.

Authors:  Aditi R Deshpande; Karina Wagenpfeil; Thomas C Pochapsky; Gregory A Petsko; Dagmar Ringe
Journal:  Biochemistry       Date:  2016-02-24       Impact factor: 3.162

6.  Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity.

Authors:  Zhen-Yong Keck; Vicky M H Sung; Susan Perkins; Judy Rowe; Sudhir Paul; T Jake Liang; Michael M C Lai; Steven K H Foung
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Inhibition of hepatitis C virus replication by arsenic trioxide.

Authors:  Der-Ren Hwang; Yuan-Chin Tsai; Jin-Ching Lee; Kuo-Kuei Huang; Ren-Kuo Lin; Chia-Hua Ho; Jeng-Min Chiou; Ying-Ting Lin; John T A Hsu; Chau-Ting Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.

Authors:  Shane W Oram; Junkui Ai; Gina M Pagani; Moira R Hitchens; Jeffrey A Stern; Scott Eggener; Michael Pins; Wuhan Xiao; Xiaoyan Cai; Riffat Haleem; Feng Jiang; Thomas C Pochapsky; Lizbeth Hedstrom; Zhou Wang
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

Review 9.  Towards a small animal model for hepatitis C.

Authors:  Alexander Ploss; Charles M Rice
Journal:  EMBO Rep       Date:  2009-10-16       Impact factor: 8.807

10.  ADI1, a methionine salvage pathway enzyme, is required for Drosophila fecundity.

Authors:  He-Yen Chou; Yu-Hung Lin; Guan-Lin Shiu; Hsiang-Yu Tang; Mei-Ling Cheng; Ming-Shi Shiao; Li-Mei Pai
Journal:  J Biomed Sci       Date:  2014-07-19       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.